Medico Intercontinental
- Market cap
- ₹ 23 Cr.
- P/E
- 10.9x
- P/B
- 0.5x
- 52-week range
- 20.61 – 43
- ROE
- −7%
- ROCE
- −1%
- Dividend yield
- 0%
- Debt / equity
- 1.43
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Medico Intercontinental Ltd is engaged in the business of trading pharmaceutical products. It provides a platform for all research-based biopharmaceutical companies. Its product categories include Gastro, Uro, Nutrition, Cosmetology, Health devices, Hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE-D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT-4, ZIFT SL-250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY, RELIBEN SUSP, ZIFT SUSP-200, MGCIPACT EYE DROP, OROFACT-PASTE (lamy), OROFACT MOUTH ULCER GEL, CAMBOGIA, LUBRIACT, HIZEN, and CALAMED LOTION. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Medico Intercontinental against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)10.9 against a typical 28.5: cheaper than most peers (1st = cheapest).45th of 186
- Sales growth−3% against a typical −2.4% from a year earlier.73rd of 143
- Share price, 3 months+1% against a typical −4.9%.50th of 169
- Size₹ 23.5 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).95th of 183
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 14 | 16 | 19 | 36 | 18 | 21 | 21 | 20 | 20 | 22 | 21 |
| Expenses | 16 | 13 | 14 | 18 | 34 | 17 | 19 | 21 | 21 | 18 | 21 | 21 |
| Operating Profit | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 1 | −1 | 2 | 2 | −1 |
| OPM % | 7.7% | 10.5% | 9.9% | 8.5% | 7.4% | 10.4% | 9.2% | 3.2% | −4.3% | 8% | 7.2% | −3.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 2 | 2 | 1 | −2 | −4 | −1 | −2 | −4 |
| Tax % | 29.3% | 26.1% | 28.3% | 27.5% | 29.6% | 27.4% | 22.5% | 23.9% | 4.6% | 20% | 51.3% | 10.3% |
| Net Profit | 1 | 1 | 1 | 1 | 2 | 1 | 1 | −2 | −5 | −2 | −2 | −4 |
| EPS in Rs | 0.87 | 1.02 | 1.04 | 1.08 | 1.63 | 1.17 | 1.17 | −0.68 | −1.65 | −0.22 | −0.65 | −1.45 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 4%
- 3 Years
- 3%
- TTM
- −14%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −221%
- 10 Years
- —
- 5 Years
- −9%
- 3 Years
- −30%
- TTM
- —
- 10 Years
- —
- 5 Years
- 7%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Medico Intercontinental | ₹ 25.00 | ₹ 23 Cr. | 10.9x | 0.5x | −7% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.8x | 5.8x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 79.3x | 12.4x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.4x | 19.7x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.5x | 3.4x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.1x | 19.7% | 18.5% |
Prices are delayed and for information only. Nothing on this page is investment advice.